Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

References

• AntochGKanjaJBauerSComparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumorsJ Nucl Med2004453576515001674
   PubMed Web of Science ®Google Scholar
• AntonescuCRBesmerPGuoTAcquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutationClin Cancer Res20051141829015930355
   PubMed Web of Science ®Google Scholar
• BauerSHartmannJTDe WitMResection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinibInt J Cancer20051173162515900603
   PubMed Web of Science ®Google Scholar
• BauerSYuLDemetriGDHeat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumorCancer Res20066691536116982758
   PubMed Web of Science ®Google Scholar
• BenjaminRSBlankeCDBlayJYManagement of gastrointestinal stromal tumors in the imatinib era: selected case studiesOncologist20061192016401709
   PubMed Web of Science ®Google Scholar
• BenjaminRSChoiHMacapinlacHAWe should desist using RECIST, at least in GISTJ Clin Oncol2007251760417470866
   PubMed Web of Science ®Google Scholar
• BenjaminRSRankinCFletcherCPhase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early resultsProc Am Soc Clin Oncol200322
   Google Scholar
• BerindoagueRTargaronaEMFeliuXLaparoscopic resection of clinically suspected gastric stromal tumorsSurg Innov200613231717227921
   PubMed Web of Science ®Google Scholar
• BertucciFGoncalvesAMongesGAcquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumourOncol Rep2006169710116786129
   PubMed Web of Science ®Google Scholar
• BlankeCJoensuuHDemetriGLong-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylateProc Am Soc Clin Oncol GI Cancer Symposium20042
   Google Scholar
• BlayJYBonvalotSCasaliPConsensus meeting for the management of gastrointestinal stromal tumorsAnn Oncol200516Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO56678 erratum appears in Ann Oncol. 2005 Jun; 16(6):993 Note: Mac Clure, J [corrected to McClure, J15781488
   PubMedGoogle Scholar
• BlayJYLe CesneARay-CoquardIProspective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma GroupJ Clin Oncol20072511071317369574
   PubMed Web of Science ®Google Scholar
• BucherPEggerJFGervazPAn audit of surgical management of gastrointestinal stromal tumours (GIST)Eur J Surg Oncol200632310416414236
   PubMed Web of Science ®Google Scholar
• BurgerHDen BakkerMAKrosJMActivating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genesCancer Biol Ther2005412704 see comment16294026
   PubMed Web of Science ®Google Scholar
• CarneyJAShepsSGGoVLThe triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondromaN Engl J Med197729615178865533
   PubMed Web of Science ®Google Scholar
• CarrollMOhno-JonesSTamuraSCGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteinsBlood1997904947529389713
   PubMed Web of Science ®Google Scholar
• ChenHPruittANicolTLComplete hepatic resection of metastases from leiomyosarcoma prolongs survivalJ Gastrointest Surg1998215159834411
   PubMedGoogle Scholar
• ChoiHCharnsangavejCFariaSCCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteriaJ Clin Oncol2007251753917470865
   PubMed Web of Science ®Google Scholar
• CorlessCLFletcherJAHeinrichMCBiology of gastrointestinal stromal tumorsJ Clin Oncol20042238132515365079
   PubMed Web of Science ®Google Scholar
• D’AmatoGSteinertDMMcAuliffeJCUpdate on the biology and therapy of gastrointestinal stromal tumorsCancer Control200512445615668652
   PubMedGoogle Scholar
• DeGiorgiUVerweijJImatinib and gastrointestinal stromal tumors: Where do we go from here?Mol Cancer Ther2005449550115767559
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMLasotaJSarlomo-RikalaMChromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutationCancer Genet Cytogenet2001128243011454425
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMSciotRLe CesneAKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEur J Cancer200642109310316624552
   PubMed Web of Science ®Google Scholar
• DeMatteoROwzarKMakiRACOSOG AIAGSAdjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z900120072007 ASCO Annual Meeting, 10079
   Google Scholar
• DeMatteoRPHeinrichMCEl-RifaiWMClinical management of gastrointestinal stromal tumors: before and after STI-571Hum Pathol2002334667712094371
   PubMed Web of Science ®Google Scholar
• DeMatteoRPLewisJJLeungDTwo hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survivalAnn Surg200023151810636102
   PubMed Web of Science ®Google Scholar
• DemetriGDVan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636813293817046465
   PubMed Web of Science ®Google Scholar
• DemetriGDVon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med20023474728012181401
   PubMed Web of Science ®Google Scholar
• DesaiJYassaLMarquseeEHypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumorsAnn Intern Med2006145660417088579
   PubMed Web of Science ®Google Scholar
• DoiTNishidaTHirotaSPhase II clinical study of STI571 in Japanese (Jpn) patients (pts) with malignant gastrointestinal stromal tumors (GIST): Results of the B 1201 studyJ Clin Oncol2004224078
   Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med20013441031711287972
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med1996256168616716
   PubMed Web of Science ®Google Scholar
• ErnstSIHubbsAEPrzygodzkiRMKIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumorsLab Invest199878163369881963
   PubMed Web of Science ®Google Scholar
• FletcherCDBermanJJCorlessCDiagnosis of gastrointestinal stromal tumors: A consensus approachHum Pathol2002334596512094370
   PubMed Web of Science ®Google Scholar
• FletcherJACorlessCLDimitrijevicSMechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST)Proc Am Soc Clin Oncol200322
   PubMedGoogle Scholar
• GoerresGWStuppRBarghouthGThe value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylateEur J Nucl Med Mol Imaging2005321536215690223
   PubMed Web of Science ®Google Scholar
• GunawanBBergmannFHoerJBiological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumorsHum Pathol2002333162111979372
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLDemetriGDKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorJ Clin Oncol2003a214342914645423
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLDuensingAPDGFRA activating mutations in gastrointestinal stromal tumorsScience2003b2997081012522257
   PubMed Web of Science ®Google Scholar
• HeinrichMCGriffithDJDrukerBJInhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitorBlood2000969253210910906
   PubMed Web of Science ®Google Scholar
• HirotaSIsozakiKMoriyamaYGain-of-function mutations of c-kit in human gastrointestinal stromal tumorsScience1998279577809438854
   PubMed Web of Science ®Google Scholar
• HirotaSOhashiANishidaTGain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumorsGastroenterology2003125660712949711
   PubMed Web of Science ®Google Scholar
• IshidaTWadaIHoriuchiHMultiple small intestinal stromal tumors with skeinoid fibers in association with neurofibromatosis 1 (von Recklinghausen’s disease)Pathol Int199646689958905879
   PubMed Web of Science ®Google Scholar
• JoensuuHSunitinib for imatinib-resistant GISTLancet20063681303417046443
   PubMed Web of Science ®Google Scholar
• JoensuuHFletcherCDimitrijevicSManagement of malignant gastrointestinal stromal tumoursLancet Oncol200236556412424067
   PubMed Web of Science ®Google Scholar
• JoensuuHRobertsPJSarlomo-RikalaMEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorN Engl J Med20013441052611287975
   PubMed Web of Science ®Google Scholar
• JudsonIMaPPengBImatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupCancer Chemother Pharmacol2005553798615592836
   PubMed Web of Science ®Google Scholar
• KasperBKallinowskiBHerrmannTTreatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in HeidelbergDig Dis2006242071116699280
   PubMed Web of Science ®Google Scholar
• KindblomLGRemottiHEAldenborgFGastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of CajalAm J Pathol19981521259699588894
   PubMed Web of Science ®Google Scholar
• KingDMThe radiology of gastrointestinal stromal tumours (GIST)Cancer Imaging20055150616361144
   PubMedGoogle Scholar
• KosmadakisNVisvardisEEKartsaklisPThe role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectivenessSurg Oncol200514758415993051
   PubMed Web of Science ®Google Scholar
• LasotaJJasinskiMSarlomo-RikalaMMutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomasAm J Pathol199915453609916918
   PubMed Web of Science ®Google Scholar
• Le CesneARay-CoquardIBuiMContinuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma GroupJ Clin Oncol2007252007 ASCO Annual Meeting Proceedings, Part I18S June 20 Supplement10005
   Google Scholar
• LiSQO’LearyTJSobinLHAnalysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumorsActa Cytol200044981611127756
   PubMed Web of Science ®Google Scholar
• LintonKMTaylorMBRadfordJAResponse evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastasesBr JRadiol200679e40416861316
   PubMedGoogle Scholar
• LoughreyMBMitchellCMannGBGastrointestinal stromal tumour treated with neoadjuvant imatinibJ Clin Pathol2005587798115976351
   PubMed Web of Science ®Google Scholar
• MavligitGMZukwiskiAAEllisLMGastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastineCancer199575208387697597
   PubMed Web of Science ®Google Scholar
• MazurMTClarkHBGastric stromal tumors. Reappraisal of histogenesisAm J Surg Pathol19837507196625048
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosisVirchows Arch200143811211213830
   PubMed Web of Science ®Google Scholar
• MiettinenMMajidiMLasotaJPathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a reviewEur J Cancer200238S395112528772
   PubMed Web of Science ®Google Scholar
• MiettinenMMakhloufHSobinLHGastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-upAm J Surg Pathol2006304778916625094
   PubMed Web of Science ®Google Scholar
• MiettinenMSobinLHLasotaJGastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-upAm J Surg Pathol200529526815613856
   PubMed Web of Science ®Google Scholar
• MiettinenMVirolainenMMaarit SarlomoRGastrointestinal stromal tumors – value of CD34 antigen in their identification and separation from true leiomyomas and schwannomasAm J Surg Pathol199519207167530409
   PubMed Web of Science ®Google Scholar
• NCIGIST clinical trials search [online]2007 Accessed 5 May 2007. URL: http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid=2096061
   Google Scholar
• NeuhausSJClarkMAHayesAJSurgery for gastrointestinal stromal tumour in the post-imatinib eraANZ J Surg2005751657215777399
   PubMed Web of Science ®Google Scholar
• NgEHPollockREMunselLMFPrognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and stagingAnn Surg199221568771731651
   PubMed Web of Science ®Google Scholar
• NilssonBBummingPMeis-KindblomJMGastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western SwedenCancer2005103821915648083
   PubMed Web of Science ®Google Scholar
• NovartisGlivec (imatinib) Summary of Product Characteristics2005
   Google Scholar
• NovitskyYWKercherKWSingRFLong-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumorsAnn Surg200624373845 discussion 745–716772777
   PubMed Web of Science ®Google Scholar
• PengBLloydPSchranHClinical pharmacokinetics of imatinibClin Pharmacokinetics20054487994
   PubMed Web of Science ®Google Scholar
• PlaatBEHollemaHMolenaarWMSoft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteinsJ Clin Oncol20001832112010986053
   PubMed Web of Science ®Google Scholar
• RajanDKSoulenMCClarkTWSarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolizationJ Vasc Interv Radiol2001121879311265882
   PubMed Web of Science ®Google Scholar
• RankinCVon MehrenMBlankeCDose effect of imatinib (IM) in patients (pts) with metastatic GIST – Phase III Sarcoma Group Study S0033Proc Am Soc Clin Oncol200422
   PubMedGoogle Scholar
• RautCPPosnerMDesaiJSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitorsJ Clin Oncol20062423253116710031
   PubMed Web of Science ®Google Scholar
• RubinBPSingerSTsaoCKIT activation is a ubiquitous feature of gastrointestinal stromal tumorsCancer Res20016181182111719439
   PubMed Web of Science ®Google Scholar
• RutkowskiPNoweckiZIMichejWRisk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumorAnn Surg Oncol20071420182717473953
   PubMed Web of Science ®Google Scholar
• RyuMHLeeJLChangHMPatterns of progression in gastrointestinal stromal tumor treated with imatinib mesylateJpn J Clin Oncol200636172416418188
   PubMed Web of Science ®Google Scholar
• SakakuraCHagiwaraASogaKLong-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomyWorld J Gastroenterol2006122793716718773
   PubMed Web of Science ®Google Scholar
• SanbornREBlankeCDGastrointestinal stromal tumors and the evolution of targeted therapyClin Adv Hematol Oncol200536475716167051
   PubMedGoogle Scholar
• SavageDGAntmanKHImatinib mesylate – a new oral targeted therapyN Engl J Med20023466839311870247
   PubMed Web of Science ®Google Scholar
• SchindlerCGArmbrustTGunawanBGastrointestinal stromal tumor (GIST) – single center experience of prolonged treatment with imatinibZ Gastroenterol2005432677315765299
   PubMed Web of Science ®Google Scholar
• ShankarSVansonnenbergEDesaiJGastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylateRadiology2005235892815833985
   PubMed Web of Science ®Google Scholar
• SihtoHSarlomo-RikalaMTynninenOKIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumorsJ Clin Oncol200523495715545668
   PubMed Web of Science ®Google Scholar
• SteigenSEEideTJWasagBMutations in gastrointestinal stromal tumors – a population-based study from Northern NorwayAPMIS20071152899817504295
   PubMed Web of Science ®Google Scholar
• StroobantsSGoeminneJSeegersM18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)Eur J Cancer200339201220 see comment12957455
   PubMed Web of Science ®Google Scholar
• TakahashiHSaitohKKishiHImmunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumoursVirchows Arch199542728387496598
   PubMed Web of Science ®Google Scholar
• TaniguchiMNishidaTHirotaSEffect of c-kit mutation on prognosis of gastrointestinal stromal tumorsCancer Res199959429730010485475
   PubMed Web of Science ®Google Scholar
• Van Der ZwanSMDematteoRPGastrointestinal stromal tumor: 5 years laterCancer20051041781816136600
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMVerweijJCasaliPGInitial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyJ Clin Oncol200523579580416110036
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMMOwzarKRankinCMETAGISTGM-AGComparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts)J Clin Oncol2007252007 ASCO Annual Meeting Proceedings, Part I18S June 20 Supplement10004
   Google Scholar
• Van OosteromATJudsonIRVerweijJSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyLancet20013581421311705489
   PubMed Web of Science ®Google Scholar
• Van OosteromATJudsonIRVerweijJEuropean Organisation for Research and Treatment of Cancer Soft Tissue and Bone SarcomaUpdate of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma GroupEur J Cancer200238S83712528778
   PubMed Web of Science ®Google Scholar
• VerweijJCasaliPGZalcbergJProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialLancet2004364112734 see comment15451219
   PubMed Web of Science ®Google Scholar
• VerweijJVan OosteromABlayJYImatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyEur J Cancer200339200611 see comment12957454
   PubMed Web of Science ®Google Scholar
• WardelmannEHrychykAMerkelbach-BruseSAssociation of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumorsJ Mol Diagn2004619720415269295
   PubMed Web of Science ®Google Scholar
• WardelmannEMerkelbach-BruseSPaulsKPolyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylateClin Cancer Res20061217439 see comment16551858
   PubMed Web of Science ®Google Scholar
• WardelmannEThomasNMerkelbach-BruseSAcquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutationsLancet Oncol200562495115811621
   PubMed Web of Science ®Google Scholar
• WentPTDirnhoferSBundiMPrevalence of KIT expression in human tumorsJ Clin Oncol20042245142215542802
   PubMed Web of Science ®Google Scholar
• WestRBCorlessCLChenXThe novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation statusAm J Pathol20041651071315215166
   PubMed Web of Science ®Google Scholar
• WuPCLangermanARyanCWSurgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) eraSurgery20031346566514605627
   PubMed Web of Science ®Google Scholar